Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.[3]
Medical uses
Zotepine's primary use is as a treatment for schizophrenia[4] although clinical trials have been conducted (with positive results) into its efficacy as an antimanic agent in patients with acute bipolar mania.[5][6][7] In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, zotepine demonstrated medium-strong effectivity. Less effective than
clozapine, slightly less effective than
olanzapine and
risperidone, approximately as effective as
paliperidone, and slightly more effective than
haloperidol,
quetiapine, and
aripiprazole.[8]
Weight gain (produces a similar degree of weight gain to that seen with
clozapine and
olanzapine treatment)[9]
Somnolence (2nd highest effect size for causing sedation out of fifteen antipsychotics compared in a recent meta-analysis)[9]
Extrapyramidal side effects [EPSE] (2nd largest
odds ratio for causing EPSE out of fifteen antipsychotics compared in a recent meta-analysis, second only to haloperidol)[9]
Brand names include Losizopilon (
JP), Lodopin (
ID,
JP), Setous (
JP), Zoleptil (
CZ,
PT,
TR,
UK†); where † indicates a formulation that has been discontinued.
^Harada T, Otsuki S (1986). "Antimanic effect of zotepine". Clinical Therapeutics. 8 (4): 406–14.
PMID3089626.
^Amann B, Sterr A, Mergl R, Dittmann S, Seemüller F, Dobmeier M, et al. (October 2005). "Zotepine loading in acute and severely manic patients: a pilot study". Bipolar Disorders. 7 (5): 471–6.
doi:
10.1111/j.1399-5618.2005.00241.x.
PMID16176441.
^Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62.
doi:
10.1016/S0140-6736(13)60733-3.
PMID23810019.
S2CID32085212.
^
abcLeucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62.
doi:
10.1016/S0140-6736(13)60733-3.
PMID23810019.
S2CID32085212.
^
abNational Institute of Mental Health (12 January 2011).
"PDSD Ki Database". Chapel Hill (NC): University of North Carolina. Archived from
the original on November 8, 2013. Retrieved 2 November 2013.
^Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, et al. (June 2010). "Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake". The Journal of Pharmacology and Experimental Therapeutics. 333 (3): 772–81.
doi:
10.1124/jpet.110.166264.
PMID20223878.
S2CID185592.
Zotepine is not approved for use in the United States, United Kingdom, Australia, Canada or New Zealand.[3]
Medical uses
Zotepine's primary use is as a treatment for schizophrenia[4] although clinical trials have been conducted (with positive results) into its efficacy as an antimanic agent in patients with acute bipolar mania.[5][6][7] In a 2013 study in a comparison of 15 antipsychotic drugs in effectivity in treating schizophrenic symptoms, zotepine demonstrated medium-strong effectivity. Less effective than
clozapine, slightly less effective than
olanzapine and
risperidone, approximately as effective as
paliperidone, and slightly more effective than
haloperidol,
quetiapine, and
aripiprazole.[8]
Weight gain (produces a similar degree of weight gain to that seen with
clozapine and
olanzapine treatment)[9]
Somnolence (2nd highest effect size for causing sedation out of fifteen antipsychotics compared in a recent meta-analysis)[9]
Extrapyramidal side effects [EPSE] (2nd largest
odds ratio for causing EPSE out of fifteen antipsychotics compared in a recent meta-analysis, second only to haloperidol)[9]
Brand names include Losizopilon (
JP), Lodopin (
ID,
JP), Setous (
JP), Zoleptil (
CZ,
PT,
TR,
UK†); where † indicates a formulation that has been discontinued.
^Harada T, Otsuki S (1986). "Antimanic effect of zotepine". Clinical Therapeutics. 8 (4): 406–14.
PMID3089626.
^Amann B, Sterr A, Mergl R, Dittmann S, Seemüller F, Dobmeier M, et al. (October 2005). "Zotepine loading in acute and severely manic patients: a pilot study". Bipolar Disorders. 7 (5): 471–6.
doi:
10.1111/j.1399-5618.2005.00241.x.
PMID16176441.
^Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62.
doi:
10.1016/S0140-6736(13)60733-3.
PMID23810019.
S2CID32085212.
^
abcLeucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. (September 2013). "Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis". Lancet. 382 (9896): 951–62.
doi:
10.1016/S0140-6736(13)60733-3.
PMID23810019.
S2CID32085212.
^
abNational Institute of Mental Health (12 January 2011).
"PDSD Ki Database". Chapel Hill (NC): University of North Carolina. Archived from
the original on November 8, 2013. Retrieved 2 November 2013.
^Shobo M, Kondo Y, Yamada H, Mihara T, Yamamoto N, Katsuoka M, et al. (June 2010). "Norzotepine, a major metabolite of zotepine, exerts atypical antipsychotic-like and antidepressant-like actions through its potent inhibition of norepinephrine reuptake". The Journal of Pharmacology and Experimental Therapeutics. 333 (3): 772–81.
doi:
10.1124/jpet.110.166264.
PMID20223878.
S2CID185592.